Pre- and postsynaptic actions of a partial D2 receptor agonist in reserpinized young rats: Longevity of agonistic effects

Brain Research

Volumn 1124, Issue 1, 2006, Pages 37-44

  Farley, Cristal M ^a   Baella, Shelley A ^a   Wacan, Jennifer J ^a   Crawford, Cynthia A ^a   McDougall, Sanders A ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Dopamine synthesis; Locomotor activity; Ontogeny; Partial D2 agonist; Reserpine; Terguride

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; RESERPINE; TERGURIDE;

AGONIST; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BIOACCUMULATION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL RAT; FEMALE; LOCOMOTION; MALE; NEUROBIOLOGY; NEUROMODULATION; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; AUTORECEPTORS; BEHAVIOR, ANIMAL; BODY WEIGHT; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG INTERACTIONS; MOTOR ACTIVITY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; TIME FACTORS;

EID: 33751189585     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.09.068     Document Type: Article

References (55)

1. Arnt J. Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers. Eur. J. Pharmacol. 91 (1983) 273-278
2. Arnt J., and Hyttel J. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J. Neural Transm. 60 (1984) 205-223
3. Arnt J., and Hyttel J. Dopamine D-2 agonists with high and low efficacies: Differentiation by behavioural techniques. J. Neural Transm. 80 (1990) 33-50
4. Baldessarini R.J., Marsh E.R., and Huston-Lyons D. Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain. Biochem. Pharmacol. 47 (1994) 1917-1919
5. Barzman D.H., DelBello M.P., Kowatch R.A., Gernert B., Fleck D.E., Pathak S., Rappaport K., Delgado S.V., Campbell P., and Strakowski S.M. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J. Child Adolesc. Psychopharmacol. 14 (2004) 593-600
6. Biederman J., McDonnell M.A., Wozniak J., Spencer T., Aleardi M., Falzone R., and Mick E. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 10 (2005) 141-148
7. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
8. 2 receptor function in rats. J. Pharmacol. Exp. Ther. 266 (1993) 585-592
9. Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of the receptor. J. Neural Transm. 57 (1983) 309-315
10. Clark D., Hjorth S., and Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: I. Review of the evidence. J. Neural Transm. 62 (1985) 1-52
11. Clark D., Hjorth S., and Carlsson A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity: II. Theoretical considerations. J. Neural Transm. 62 (1985) 171-207
12. Clark D., Hjorth S., and Carlsson A. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. Eur. J. Pharmacol. 106 (1985) 185-189
13. Clark D., Furmidge L.J., Petry N., Tong Z.-Y., Ericsson M., and Johnson D. Behavioural profile of partial D2 dopamine receptor agonists: 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy. Psychopharmacology (Berlin) 105 (1991) 381-392
14. Clark D., Salah R.S., and Galloway M.P. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: Dependence on extracellular dopamine. Synapse 8 (1991) 169-176
15. Davies M.A., Sheffler D.J., and Roth B.L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 10 (2004) 317-336
16. DiLullo S.L., and Martin-Iverson M.T. Evidence for presynaptic dopamine mechanisms underlying amphetamine-conditioned locomotion. Brain Res. 578 (1992) 161-167
17. Drukarch B., and Stoof J.C. D-2 dopamine autoreceptor selective drugs: do they really exist?. Life Sci. 47 (1990) 361-376
18. Findling R.L., Blumer J., Kauffman R., Batterson J., Gilbert D., Bramer S., and Marcus R. Aripiprazole in pediatric conduct disorder: a pilot study. Eur. Neuropsychopharmacol. 13 Suppl. 4 (2003) S335
19. Hjorth S., Carlsson A., Clark D., Svensson K., Wikstrom H., Sanchez D., Lindberg P., Hacksell U., Arvidsson L.E., Johansson A., and Nilsson J.L.G. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berlin) 81 (1983) 89-99
20. Hjorth S., Clark D., and Carlsson A. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Eur. J. Pharmacol. 152 (1988) 207-215
21. Izzo E., Orsini C., Koob G.F., and Pulvirenti L. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacol. Biochem. Behav. 68 (2001) 701-708
22. 2B receptors is not a class effect of the ergolines. Eur. J. Pharmacol. 513 (2005) 225-228
23. 1A receptor. Eur. J. Pharmacol. 441 (2002) 137-140
24. Kehr W. Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Eur. J. Pharmacol. 97 (1984) 111-119
25. Kohler W.C., and Herbster G. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology 37 (1987) 723-727
26. 2A receptors of rat tail artery. Physiol. Res. 53 (2004) 35-43
27. LaHoste G.J., and Marshall J.F. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse 12 (1992) 14-26
28. LaHoste G.J., Yu J., and Marshall J.F. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7451-7455
29. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., and Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
30. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493 (2004) 75-83
31. 2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats. Psychopharmacology (Berlin) 178 (2005) 431-439
32. Meller E., Helmer-Matyjek E., Bohmaker K., Adler C.H., Friedhoff A.J., and Goldstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur. J. Pharmacol. 123 (1986) 311-314
33. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., and Goldstein M. Relationship between receptor occupancy and response at striatal autoreceptors. Mol. Pharmacol. 31 (1987) 592-598
34. Meller E., Enz A., and Goldstein M. Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur. J. Pharmacol. 155 (1988) 151-154
35. Murphy T.K., Bengtson M.A., Soto O., Edge P.J., Sajid M.W., Shapira N., and Yang M. Case series on the use of aripiprazole for Tourette syndrome. Int. J. Neuropsychopharmacol. 8 (2005) 489-490
36. National Research Council. Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (2003), National Academy Press, Washington
37. 2, receptor subtypes. J. Pharmacol. Exp. Ther. 303 (2002) 815-822
38. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 341-356
39. Oshiro Y., Sato S., Kurahashi N., Tanaka T., Kikuchi T., Tottori K., Uwahodo Y., and Nishi T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J. Med. Chem. 41 (1998) 658-667
40. Platt D.M., Rodefer J.S., Rowlett J.K., and Spealman R.D. Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology (Berlin) 166 (2003) 298-305
41. Pulvirenti L., and Koob G.F. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. 15 (1994) 374-379
42. Pulvirenti L., Balducci C., Piercy M., and Koob G.F. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J. Pharmacol. Exp. Ther. 286 (1998) 1231-1238
43. Rubinstein M., Muschietti J.P., Gershanik O., Flawia M.M., and Stefano F.J. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J. Pharmacol. Exp. Ther. 252 (1990) 810-816
44. Rugino T.A., and Janvier Y.M. Aripiprazole in children and adolescents: clinical experience. J. Child Neurol. 20 (2005) 603-610
45. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
46. 2-like agonist on the cocaine-induced behavioral sensitization of preweanling rats. Pharmacol. Biochem. Behav. 76 (2003) 27-34
47. Stigler K.A., Posey D.J., and McDougle C.J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 14 (2004) 455-463
48. Svensson K., Ekman A., Piercey M.F., Hoffmann W.E., Lum J.T., and Carlsson A. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn-Schmiedebergs Arch. Pharmacol. 344 (1991) 263-274
49. Svensson K., Eriksson E., and Carlsson A. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 32 (1993) 1037-1045
50. Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 109 (2002) 411-420
51. 2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen. Psychopharmacology (Berlin) 185 (2006) 104-111
52. Wachtel H., and Dorow R. Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci. 32 (1983) 421-432
53. Wachtel H., Rettig K.-J., and Seltz A. The central dopamine agonistic action of transdihydrolisuride is unmasked at supersensitive receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 325 (1984) R80
54. 2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats. Brain Res. 1073/1074 (2006) 269-275
55. Zorrilla E.P. Multiparous species present problems (and possibilities) to developmentalists. Dev. Psychobiol. 30 (1997) 141-150